vs

Side-by-side financial comparison of NN INC (NNBR) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $104.7M, roughly 2.0× NN INC). NN INC runs the higher net margin — -12.0% vs -62.0%, a 50.0% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -1.7%). NN INC produced more free cash flow last quarter ($-3.3M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -7.0%).

NN Group N.V. is the parent company of NN Investment Partners and Nationale-Nederlanden. Nationale-Nederlanden is one of the largest insurance and asset management companies in the Netherlands. NN Group is headquartered in The Hague, its office in Rotterdam is located in the skyscraper Gebouw Delftse Poort, which was the tallest skyscraper in the Netherlands until 2009. Aside from these two offices, the company has an office in Ede but no other main offices in the Netherlands, instead NN main...

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

NNBR vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
2.0× larger
RARE
$207.3M
$104.7M
NNBR
Growing faster (revenue YoY)
RARE
RARE
+27.6% gap
RARE
25.9%
-1.7%
NNBR
Higher net margin
NNBR
NNBR
50.0% more per $
NNBR
-12.0%
-62.0%
RARE
More free cash flow
NNBR
NNBR
$97.5M more FCF
NNBR
$-3.3M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-7.0%
NNBR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NNBR
NNBR
RARE
RARE
Revenue
$104.7M
$207.3M
Net Profit
$-12.5M
$-128.6M
Gross Margin
Operating Margin
-9.9%
-54.7%
Net Margin
-12.0%
-62.0%
Revenue YoY
-1.7%
25.9%
Net Profit YoY
40.2%
3.5%
EPS (diluted)
$-0.35
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NNBR
NNBR
RARE
RARE
Q4 25
$104.7M
$207.3M
Q3 25
$103.9M
$159.9M
Q2 25
$107.9M
$166.5M
Q1 25
$105.7M
$139.3M
Q4 24
$106.5M
$164.6M
Q3 24
$113.6M
$139.5M
Q2 24
$123.0M
$147.0M
Q1 24
$121.2M
$108.8M
Net Profit
NNBR
NNBR
RARE
RARE
Q4 25
$-12.5M
$-128.6M
Q3 25
$-6.7M
$-180.4M
Q2 25
$-8.1M
$-115.0M
Q1 25
$-6.7M
$-151.1M
Q4 24
$-21.0M
$-133.2M
Q3 24
$-2.6M
$-133.5M
Q2 24
$-2.2M
$-131.6M
Q1 24
$-12.5M
$-170.7M
Operating Margin
NNBR
NNBR
RARE
RARE
Q4 25
-9.9%
-54.7%
Q3 25
-2.2%
-106.9%
Q2 25
-1.4%
-64.8%
Q1 25
-4.5%
-102.6%
Q4 24
-15.8%
-74.3%
Q3 24
-3.3%
-94.6%
Q2 24
-1.7%
-79.1%
Q1 24
-3.9%
-151.9%
Net Margin
NNBR
NNBR
RARE
RARE
Q4 25
-12.0%
-62.0%
Q3 25
-6.4%
-112.8%
Q2 25
-7.5%
-69.0%
Q1 25
-6.3%
-108.5%
Q4 24
-19.7%
-80.9%
Q3 24
-2.3%
-95.7%
Q2 24
-1.8%
-89.5%
Q1 24
-10.3%
-156.8%
EPS (diluted)
NNBR
NNBR
RARE
RARE
Q4 25
$-0.35
$-1.28
Q3 25
$-0.23
$-1.81
Q2 25
$-0.26
$-1.17
Q1 25
$-0.23
$-1.57
Q4 24
$-0.52
$-1.34
Q3 24
$-0.13
$-1.40
Q2 24
$-0.12
$-1.52
Q1 24
$-0.34
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NNBR
NNBR
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$11.4M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$34.0M
$-80.0M
Total Assets
$440.8M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NNBR
NNBR
RARE
RARE
Q4 25
$11.4M
$421.0M
Q3 25
$12.2M
$202.5M
Q2 25
$9.5M
$176.3M
Q1 25
$11.7M
$127.1M
Q4 24
$18.1M
$174.0M
Q3 24
$12.4M
$150.6M
Q2 24
$13.7M
$480.7M
Q1 24
$20.6M
$112.3M
Stockholders' Equity
NNBR
NNBR
RARE
RARE
Q4 25
$34.0M
$-80.0M
Q3 25
$49.6M
$9.2M
Q2 25
$59.5M
$151.3M
Q1 25
$67.3M
$144.2M
Q4 24
$74.5M
$255.0M
Q3 24
$106.6M
$346.8M
Q2 24
$108.4M
$432.4M
Q1 24
$116.1M
$140.3M
Total Assets
NNBR
NNBR
RARE
RARE
Q4 25
$440.8M
$1.5B
Q3 25
$451.0M
$1.2B
Q2 25
$460.8M
$1.3B
Q1 25
$460.7M
$1.3B
Q4 24
$456.9M
$1.5B
Q3 24
$483.1M
$1.5B
Q2 24
$497.2M
$1.6B
Q1 24
$512.8M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NNBR
NNBR
RARE
RARE
Operating Cash FlowLast quarter
$-1.5M
$-99.8M
Free Cash FlowOCF − Capex
$-3.3M
$-100.8M
FCF MarginFCF / Revenue
-3.2%
-48.6%
Capex IntensityCapex / Revenue
1.8%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.2M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NNBR
NNBR
RARE
RARE
Q4 25
$-1.5M
$-99.8M
Q3 25
$11.2M
$-91.4M
Q2 25
$-696.0K
$-108.3M
Q1 25
$-3.3M
$-166.5M
Q4 24
$6.7M
$-79.3M
Q3 24
$5.0M
$-67.0M
Q2 24
$-1.3M
$-77.0M
Q1 24
$712.0K
$-190.7M
Free Cash Flow
NNBR
NNBR
RARE
RARE
Q4 25
$-3.3M
$-100.8M
Q3 25
$7.7M
$-92.7M
Q2 25
$-4.4M
$-110.7M
Q1 25
$-7.3M
$-167.8M
Q4 24
$3.7M
$-79.5M
Q3 24
$-1.3M
$-68.6M
Q2 24
$-4.9M
$-79.0M
Q1 24
$-4.7M
$-193.9M
FCF Margin
NNBR
NNBR
RARE
RARE
Q4 25
-3.2%
-48.6%
Q3 25
7.4%
-58.0%
Q2 25
-4.1%
-66.5%
Q1 25
-6.9%
-120.5%
Q4 24
3.5%
-48.3%
Q3 24
-1.2%
-49.2%
Q2 24
-4.0%
-53.7%
Q1 24
-3.9%
-178.2%
Capex Intensity
NNBR
NNBR
RARE
RARE
Q4 25
1.8%
0.5%
Q3 25
3.3%
0.8%
Q2 25
3.4%
1.5%
Q1 25
3.7%
1.0%
Q4 24
2.8%
0.1%
Q3 24
5.5%
1.2%
Q2 24
2.9%
1.4%
Q1 24
4.5%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NNBR
NNBR

Automotive$53.1M51%
Power Solutions$45.5M43%
Other End Market$4.7M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons